about
Therapeutic Implications of Targeting AKT Signaling in MelanomaMig-7 linked to vasculogenic mimicryRheb inhibits C-raf activity and B-raf/C-raf heterodimerizationRegulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independentRealizing the clinical potential of cancer nanotechnology by minimizing toxicologic and targeted delivery concernsIn situ photoimmunotherapy: a new hope for cutaneous melanoma patients.Targeting Akt3 signaling in malignant melanoma using isoselenocyanates.A nonradioactive plate-based assay for stimulators of nonspecific DNA nicking by HIV-1 integrase and other nucleases.Identification of glycogen synthase kinase 3α as a therapeutic target in melanomaUse of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer TherapyMacrophage inhibitory cytokine-1 regulates melanoma vascular developmentAberrant CpG-island methylation has non-random and tumour-type-specific patterns.Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NF kappaB and microRNA network.Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis developmentRobust activation of the human but not mouse telomerase gene during the induction of pluripotency.KLF6 Gene and early melanoma development in a collagen I-rich extracellular environment.Evaluation of a system to screen for stimulators of non-specific DNA nicking by HIV-1 integrase: application to a library of 50,000 compounds.Leelamine mediates cancer cell death through inhibition of intracellular cholesterol transport.Targeting multiple key signaling pathways in melanoma using leelamine.Nanolipolee-007, a novel nanoparticle-based drug containing leelamine for the treatment of melanoma.eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206.Melanoma chemoprevention in skin reconstructs and mouse xenografts using isoselenocyanate-4.Growth inhibitory effects of large subunit ribosomal proteins in melanoma.Disruption of Proline Synthesis in Melanoma Inhibits Protein Production Mediated by the GCN2 Pathway.A non-cytotoxic N-dehydroabietylamine derivative with potent antimalarial activityTargeting sphingosine kinase-1 to inhibit melanoma.The Akt signaling pathway: an emerging therapeutic target in malignant melanoma.Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia.Functional and therapeutic significance of Akt deregulation in malignant melanoma.Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.Therapeutic interventions to disrupt the protein synthetic machinery in melanomaPeroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines.Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanomaPtena and ptenb genes play distinct roles in zebrafish embryogenesis.Is B-Raf a good therapeutic target for melanoma and other malignancies?Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates.Predicting therapy response in live tumor cells isolated with the flexible micro spring array device.Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation.Use of liposomes as drug delivery vehicles for treatment of melanoma.Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases
P50
Q24631438-55248F68-0E69-40A7-A5F2-0D15E67E0596Q24681666-A341AD08-BF10-4771-8288-28DD44DB9AF1Q28248759-48223F33-8E39-4360-9A9A-095C668B0277Q28262376-62C77E2B-CDA3-4852-8189-AC7B091EFC7AQ28396462-CC07F38E-9F29-4A78-BEC1-6253EC9F6F44Q30993403-19C6C7FC-CC08-4B9F-BED8-7AA6485F9425Q33408109-35756A20-3EE0-47BE-98A9-0A60DFC9D2E9Q33502482-AC801814-3742-4484-9F83-06A51FA55AE8Q33569998-B1927B1D-FBED-49F9-B081-512E76AEBB36Q33859472-D8A11DCF-2C04-40C5-9931-A1CDE8EF036AQ33882542-F37CC219-B5F9-4C3C-B20B-82B489BEB431Q33888431-B92664DE-1FE7-4965-BBA8-6E1B0074052FQ33907135-B58C6A54-13A4-4CCA-878D-001B785F06F0Q34001179-697E07EC-2F1C-45BD-B39A-A288A9BE4640Q34017109-9C1C7660-E7E1-4BB5-A398-D0E98702BE41Q34039690-C4BA26BC-52D5-4AB9-A456-BD3219B457CAQ34044741-E5F34EA2-B7E1-4532-861E-3DE0F9E25AB3Q34413011-664C6FEF-9FFB-4197-B5D0-77202DB0DC34Q35136450-DFB61AB7-BE87-4F2C-9E66-702D28484FE4Q35225907-C70551FE-6184-4E46-B309-49FAEB5861B9Q35534450-6F118B70-0093-46A6-929D-8C9422B7F587Q35535167-3403688A-7973-45B8-B3A8-EB8FFFB7D0A6Q35560443-C57EA950-38B9-4C90-8D84-DC94B6D4F201Q35665565-3CBB1258-D48D-472C-BE86-25E6D8BC344AQ35779517-CD98108C-6059-4554-B147-3FF380367915Q35789935-F2E724B9-A99D-4319-A42C-E7A9AF71BA94Q35911227-15F56A45-28E4-4964-A142-369D9B55F8ABQ36143247-71A546B5-9B07-42CC-816D-E6A2FA1B4321Q36178371-E67A0E55-D4D4-4514-B09D-41A35A3D938DQ36213487-C004353F-6384-4131-9E5F-0BA245ADD9F5Q36473355-005D7A06-9BFD-41EC-943D-22AE02100719Q36515591-51087A9C-63FE-4003-B986-D858BB70AEA7Q36536476-3477AAED-B3C0-4813-8D3E-395A5C0FD783Q37032400-83586A42-DE05-4952-BF4B-190ABFF3DAC1Q37048982-50A2DC02-ADF7-4445-8F93-0FADAABDF293Q37069862-F9A9AF64-518C-42A0-8013-C0AD3738D246Q37079780-07CB5A27-9AAD-4B93-B75F-16DB0C29FFF0Q37299513-71453438-7FDB-4839-BD65-99DF54411856Q37406217-4764B81A-2CC5-400B-B2D7-D56BD9EC52AAQ37421620-A09CAD9A-7DD7-4D4E-BAFA-FF811ADDD970
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gavin P Robertson
@nl
Gavin P Robertson
@sl
Gavin P. Robertson
@en
Gavin P. Robertson
@es
type
label
Gavin P Robertson
@nl
Gavin P Robertson
@sl
Gavin P. Robertson
@en
Gavin P. Robertson
@es
prefLabel
Gavin P Robertson
@nl
Gavin P Robertson
@sl
Gavin P. Robertson
@en
Gavin P. Robertson
@es
P106
P1153
7402368503
P21
P31
P496
0000-0003-0152-2997